Affordable access to lenacapavir
A twice-yearly HIV prevention injection, lenacapavir, will soon be available for just $40 per patient per year in 120 low- and middle-income countries. Agreements between Gilead and six generic drug manufacturers, including Dr Reddy’s and Hetero Labs, will allow distribution beginning in 2027. The price reduction is a dramatic shift from the drug’s $28,218 annual list price in the US.
A breakthrough in prevention
Lenacapavir, administered once every six months, nearly eliminated new HIV infections in clinical trials. The World Health Organization endorsed it in July, calling it “the next best thing” to a vaccine. With 1.3 million new infections worldwide last year, experts believe the injectable could reshape HIV prevention strategies. Compared to daily oral PrEP pills, the injection offers a discreet and convenient alternative, reducing stigma and adherence challenges.
Funding and partnerships
Global health organizations are backing the rollout. Unitaid, the Clinton Health Access Initiative, and Wits RHI partnered with Dr Reddy’s, while the Gates Foundation is working with Hetero Labs. The Global Fund and Pepfar also pledged early funding support, with Gilead agreeing to supply the drug at no profit until generics launch. Former US President Bill Clinton called the rollout “a genuine chance to end” the global epidemic.
Challenges and criticism
Despite optimism, experts warn the 2027 timeline may be too slow. Beatriz Grinsztejn of the International Aids Society said urgent investment is needed to reach vulnerable populations faster. Critics also raised concerns that Trump administration funding proposals would limit access only to pregnant and breastfeeding women, excluding other high-risk groups. In addition, some countries facing rising HIV cases are not included in the 120 eligible nations.